Interleukin-6, -17, and -35 levels in association with clinical status in stage III and stage IV periodontitis: a cross-sectional study
BMC Oral Health · 2024
DOI: 10.1186/s12903-024-04751-3 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift BMC Oral Health, 2024. Verfasst von Müge Altaca und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Dentistry, Department of Periodontology, Istanbul University, Istanbul, 34116, Turkey. Hauptthemen laut MEDLINE: Gingival Crevicular Fluid, Interleukin-17, Interleukin-6, Interleukins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study compared the concentrations of interleukin (IL)-6, IL-17, and IL-35 in the gingival crevicular fluid of periodontally healthy participants with individuals who had stage III and IV periodontitis.
Methods
In total, 60 participants with stage III grade B-C ( n = 12)—stage IV grade C ( n = 18) periodontitis and 30 healthy controls were included in this cross-sectional study. Full-mouth clinical periodontal measurements were performed. Concentrations of IL-6, IL-17, and IL-35 were determined using enzyme-linked immunosorbent assays. Parametric/nonparametric methods, Pearson’s/Spearman’s correlation, and logistic regression methods were used for data analyses.
Results
The periodontitis group exhibited significantly higher levels of IL-6, IL-17, and IL-35 compared with the healthy group ( p < 0.001). IL-17 levels had a positive correlation with pocket depth (PD) (r = 0.395; p = 0.031) in the periodontitis group. IL-6, IL-17, and IL-35 levels were associated with periodontitis (odds ratio [OR] = 1.344, 95% confidence interval [CI] = 1.159–1.56; OR = 1.063, 95% CI = 1.025–1.102; OR = 1.261, 95% CI = 1.110–1.434, respectively) ( p < 0.001, p = 0.001, p < 0.001, respectively). Full-mouth and sampling sites PD and clinical attachment loss (CAL) values were significantly higher in the periodontitis group than in the healthy group ( p < 0.001).
Conclusions
This study revealed upregulated levels of IL-6, IL-17, and IL-35 in periodontitis patients compared to healthy individuals. IL-17 shows a correlation with increased PD. These findings suggest a potential association between these cytokines and severe and advanced periodontitis.
Trial registration
The trial was registered in ClinicalTrials.gov with this identifier NCT05306860 on 24/01/2022.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Dentistry, Department of Periodontology, Istanbul University, Istanbul, 34116, Turkey.
- Institute of Graduate Studies in Health Sciences, Department of Periodontology, Istanbul University, Istanbul, 34126, Turkey.
- School of Dentistry, Faculty of Health and Behavioural Sciences, The University of Queensland, Brisbane, QLD, 4006, Australia.
- Faculty of Medicine, Department of Medical Biochemistry, Istanbul University, Istanbul, Turkey.
- Faculty of Dentistry, Department of Periodontology, Istanbul University, Istanbul, 34116, Turkey. emineyek@istanbul.edu.tr.
Zitieren
APA
Altaca, M., Cebesoy, E. I., Kocak-Oztug, N. A., Bingül, I., & Cifcibasi, E. (2024). Interleukin-6, -17, and -35 levels in association with clinical status in stage III and stage IV periodontitis: a cross-sectional study. BMC Oral Health. https://doi.org/10.1186/s12903-024-04751-3
Vancouver
Altaca M, Cebesoy EI, Kocak-Oztug NA, Bingül I, Cifcibasi E. Interleukin-6, -17, and -35 levels in association with clinical status in stage III and stage IV periodontitis: a cross-sectional study. BMC Oral Health. 2024. doi:10.1186/s12903-024-04751-3
BibTeX
@article{Altaca2024,
author = {Altaca, Müge and Cebesoy, Elif Ilke and Kocak-Oztug, Necla Asli and Bingül, Ilknur and Cifcibasi, Emine},
title = {Interleukin-6, -17, and -35 levels in association with clinical status in stage III and stage IV periodontitis: a cross-sectional study},
journal = {BMC Oral Health},
year = {2024},
doi = {10.1186/s12903-024-04751-3}
}
EUVIMED